Cargando…
Emerging nanomedicines for effective breast cancer immunotherapy
Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immun...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727246/ https://www.ncbi.nlm.nih.gov/pubmed/33298099 http://dx.doi.org/10.1186/s12951-020-00741-z |
_version_ | 1783621062390448128 |
---|---|
author | Bahreyni, Amirhossein Mohamud, Yasir Luo, Honglin |
author_facet | Bahreyni, Amirhossein Mohamud, Yasir Luo, Honglin |
author_sort | Bahreyni, Amirhossein |
collection | PubMed |
description | Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies. [Image: see text] |
format | Online Article Text |
id | pubmed-7727246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77272462020-12-11 Emerging nanomedicines for effective breast cancer immunotherapy Bahreyni, Amirhossein Mohamud, Yasir Luo, Honglin J Nanobiotechnology Review Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies. [Image: see text] BioMed Central 2020-12-09 /pmc/articles/PMC7727246/ /pubmed/33298099 http://dx.doi.org/10.1186/s12951-020-00741-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Bahreyni, Amirhossein Mohamud, Yasir Luo, Honglin Emerging nanomedicines for effective breast cancer immunotherapy |
title | Emerging nanomedicines for effective breast cancer immunotherapy |
title_full | Emerging nanomedicines for effective breast cancer immunotherapy |
title_fullStr | Emerging nanomedicines for effective breast cancer immunotherapy |
title_full_unstemmed | Emerging nanomedicines for effective breast cancer immunotherapy |
title_short | Emerging nanomedicines for effective breast cancer immunotherapy |
title_sort | emerging nanomedicines for effective breast cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727246/ https://www.ncbi.nlm.nih.gov/pubmed/33298099 http://dx.doi.org/10.1186/s12951-020-00741-z |
work_keys_str_mv | AT bahreyniamirhossein emergingnanomedicinesforeffectivebreastcancerimmunotherapy AT mohamudyasir emergingnanomedicinesforeffectivebreastcancerimmunotherapy AT luohonglin emergingnanomedicinesforeffectivebreastcancerimmunotherapy |